ArticleOncology letters2023

Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report.

Huan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.